A Phase II Study of TAS-109 Given by Continuous Intravenous 14-day Infusion in Patients With Chemotherapy-refractory Advanced Colorectal Cancer
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of Progression Free Survival
The primary endpoint was percentage of progression free survival as defined by the percentage of patients without progressive disease(PD)or death, whichever came first, at 3 months of therapy.
From date of randomization until date of the first documented progressive disease (PD) or death from any cause, whichever came first, assessed up to 3 months.
Henry Xiong, M.D., Ph.D.
The Center for Cancer and Blood Disorders
United States: Food and Drug Administration
|NYU Cancer Institute||New York, New York 10016|
|The University of Texas M.D. Anderson Cancer Center||Houston, Texas|
|The Center for Cancer and Blood Disorders||Fort Worth, Texas 76104|